Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen (Q21092375)

11

object named as

Jacqueline Lehmann-Che

Jacqueline

Lehmann-Che

1 reference

15 August 2022

16

Hugues de Thé

Hugues

de Thé

1 reference

15 August 2022

8

Hany Soliman

Hany

Soliman

1 reference

15 August 2022

15

Anne

Janin

Anne Janin

1 reference

15 August 2022

1

Philippe

Bertheau

Philippe Bertheau

1 reference

15 August 2022

4

Marc

Espié

Marc Espié

1 reference

15 August 2022

Louis-François Plassa

7

Louis-François

Plassa

Louis-François Plassa

1 reference

15 August 2022

9

Mariana

Varna

Mariana Varna

1 reference

15 August 2022

6

Jean-Paul

Feugeas

Jean-Paul Feugeas

1 reference

15 August 2022

10

Anne

de Roquancourt

Anne de Roquancourt

1 reference

15 August 2022

Elisabeth Turpin

2

Elisabeth

Turpin

1 reference

15 August 2022

David S Rickman

3

David S

Rickman

1 reference

15 August 2022

Yves Beuzard

12

Yves

Beuzard

1 reference

15 August 2022

Michel Marty

13

Michel

Marty

1 reference

15 August 2022

Jean-Louis Misset

14

Jean-Louis

Creative Commons Attribution 4.0 International

Misset

1 reference

15 August 2022

language of work or name

English

0 references

publication date

March 2007

0 references

published in

PLOS MEDICINE

0 references

volume

4

0 references

issue

3

0 references

page(s)

e90

0 references

copyright license

start time

20 March 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Identification of human brain tumour initiating cells

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Molecular portraits of human breast tumours

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Intrinsic tumour suppression

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

The best use of chemotherapy in the adjuvant setting

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

p53 and cancer therapy: a double-edged sword

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

A simple p53 functional assay for screening cell lines, blood, and tumors

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Factors determining cell killing by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil and nitrogen mustard

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1831731

Prognostic significance ofp53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay

29 November 2018

1 reference

12 December 2020

Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy

1 reference

12 December 2020

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

12 December 2020

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients

1 reference

12 December 2020

Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer

1 reference

12 December 2020

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401

1 reference

12 December 2020

Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression

1 reference

12 December 2020

Cancer biology: Can less be more for p53?

1 reference

12 December 2020

10.1371/JOURNAL.PMED.0040090

Identifiers

DOI

1 reference

release_yua3qbb2gnhuhiukezd54g6d54

4880182

Fatcat ID

0 references

4880182

1 reference

1 reference

1 reference